Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).
The review found no eligible studies for this question.
Cannabis‐based medicines probably leads to higher PGIC of much improved or very much improved compared with placebo medication (moderate certainty).
Cannabis‐based medicines showed no clear difference in withdrawals due to adverse events compared with placebo medication (moderate certainty).
Cannabis‐based medicines showed no clear difference in mean pain intensity (Numeric Rating Scale 0–10) compared with placebo medication (moderate certainty).
Cannabis‐based medicines showed no clear difference in daily maintenance opioid dosage (mg morphine equivalent) compared with placebo medication (low certainty).
Cannabis‐based medicines showed no clear difference in daily breakthrough opioid dosage (mg morphine equivalent) compared with placebo medication (moderate certainty).
Cannabis‐based medicines showed no clear difference in participants experiencing any serious adverse event compared with placebo medication (moderate certainty).
Mifepristone (600 mg) plus prostaglandin showed no clear difference in failure to achieve complete abortion compared with mifepristone (200 mg) plus prostaglandin (moderate certainty).
Oral misoprostol probably leads to higher failure to achieve complete abortion compared with vaginal misoprostol (moderate certainty).
Oral misoprostol may leads to higher nausea compared with vaginal misoprostol (low certainty).
The review found no eligible studies for this question.
Mifepristone (600 mg) plus prostaglandin showed no clear difference in nausea compared with mifepristone (200 mg) plus prostaglandin (moderate certainty).
The review found no eligible studies for this question.
Sublingual misoprostol showed no clear difference in failure to achieve complete abortion compared with vaginal misoprostol (moderate certainty).
Sublingual misoprostol showed no clear difference in nausea compared with vaginal misoprostol (moderate certainty).
Sublingual misoprostol showed no clear difference in women's dissatisfaction with the procedure compared with vaginal misoprostol (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether mifepristone alone changes failure to achieve complete abortion compared with mifepristone/prostaglandin (very low certainty).
The review found no eligible studies for this question.